ADC Therapeutics SA (ADCT) Misses Q4 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies
March 13, 2024 4:02 PM EDTJefferies analyst Kelly Shi lowered the price target on ADC Therapeutics (NYSE: ADCT) to $13.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "Zenlonta FY23 sales of $16.6 had been pre-announced in Jan. and we expect revenue recovery to continue in '24. The... More
